Monopar Therapeutics (MNPR) Income towards Parent Company (2017 - 2025)
Quarterly results put Income towards Parent Company at -$3.4 million for Q3 2025, down 132.97% from a year ago — trailing twelve months through Dec 2025 was -$8.5 million (down 76.24% YoY), and the annual figure for FY2024 was -$15.6 million, down 85.94%.
Monopar Therapeutics has reported Income towards Parent Company over the past 9 years, most recently at -$3.4 million for Q3 2025.
- Income towards Parent Company reached -$3.4 million in Q3 2025 per MNPR's latest filing, down from -$2.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$1.5 million in Q3 2024 and bottomed at -$14.1 million in Q4 2022.
- Median Income towards Parent Company over the past 5 years was -$2.4 million (2023), compared with a mean of -$3.0 million.
- The largest annual shift saw Income towards Parent Company crashed 424.06% in 2022 before it surged 32.59% in 2024.
- Over 5 years, Income towards Parent Company stood at -$2.7 million in 2021, then plummeted by 424.06% to -$14.1 million in 2022, then surged by 86.1% to -$2.0 million in 2023, then increased by 24.47% to -$1.5 million in 2024, then tumbled by 132.97% to -$3.4 million in 2025.
- Business Quant data shows Income towards Parent Company for MNPR at -$3.4 million in Q3 2025, -$2.5 million in Q2 2025, and -$2.6 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Monopar Therapeutics | 466.82 Mn | 466.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -2.45 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.64 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.43 Mn |
| Dec 31, 2022 | -14.05 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.76 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -2.26 Mn |
| Sep 30, 2020 | -1.65 Mn |
| Jun 30, 2020 | -1.46 Mn |
| Mar 31, 2020 | -1.14 Mn |
| Dec 31, 2019 | -1.22 Mn |
| Sep 30, 2019 | -759,448.00 |
| Jun 30, 2019 | -932,109.00 |
| Mar 31, 2019 | -1.41 Mn |
| Dec 31, 2018 | -926,358.00 |
| Sep 30, 2018 | -667,532.00 |
| Jun 30, 2018 | -667,532.00 |
| Mar 31, 2018 | -897,260.00 |
| Dec 31, 2017 | -736,800.00 |
| Sep 30, 2017 | -14.90 Mn |
| Jun 30, 2017 | -594,957.00 |
| Mar 31, 2017 | -373,839.00 |